Skip to main content

Biofrontera Inc. (BFRI)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
44.4Fair

ValueMarkers Composite Index

Top 14%#38,386 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
3.38
High Risk
Altman
-5.48
Distress
DCF Value
-
N/A
ROIC
-66.7%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Biofrontera Inc. (BFRI) — VMCI valuation read

Across 120 indicators, Biofrontera Inc. (BFRI) lands at VMCI 44/100. The Healthcare sector median is 50, so the 6-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on BFRI in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, BFRI trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -1.9x leaves covenant headroom for BFRI on the trailing balance sheet.

BFRI rose 0.9% over the trailing 7 days, with a -7.2% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BFRI’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.